Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- ...
Merck KGaA, Darmstadt, Germany regains exclusive worldwide rights to develop, manufacture and commercialize BAVENCIO from Pfizer Deal is the latest exam...
Patients treated suffered from platinum resistant/refractory ovarian cancer Previous PD-(L)1/CTLA-4 combinations have reported only 3-10% re...
ABL, a pure play Contract Development and Manufacturing Organization (CDMO) with specialized expertise in the development and manufacturing of solutions fo...
Curia, a leading contract research, development and manufacturing organization, today announced a collaboration with Corning Incorporated to expand and acc...
HANSIZHUANG (serplulimab) is the first anti-PD-1 mAb for the first-line treatment of small cell lung cancer (SCLC) The EC and the FDA previously granted...
Following the press release, the Company management will host a conference call on Friday, March 24th 2023 at 1 p.m. CET / 8 a.m. ET to discuss full year 2...
Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing...
Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a st...
SARS-CoV-2 spike protein (B.1.351 strain) vaccine is the first and only protein-based variant COVID-19 booster vaccine approved in Great Britain and the ...
© 2024 Biopharma Boardroom. All Rights Reserved.
